Is Lifeward Ltd. (LFWD) a Buy, Sell, or Hold?
NASDAQ : LFWD
Lifeward Ltd.
$7.91 USD
$0.07 (0.89%)
- Volume
- 14.86K
- Average Volume
- 12.23K
- Market Capitalization
- $12.74M
- P/E Ratio
- -0.40
- Dividend Yield
- 0.00%
- Price Target
- $129.00
- Year High
- $10.56
- Year Low
- $4.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.40
Company Overview
NASDAQ
William Mark Grant
Medical - Devices
Healthcare
LFWD
81
IL
USD
Liquidity Metrics
1.40
2.40
1.82
1.07
0.00
Sales & Valuation
$22.03M
0.61
2.03
-0.85
-9.32
Profitability
-$17.16
-$19.91M
-123.66%
-155.31%
-243.14%
-77.42%
P/E Metrics
-0.40
-0.01
-0.01
Analyst Price Target & Rating
$129.00
$156.00
$102.00
1/5
5 Analysts
-93.87%
Poll Results
About Lifeward Ltd. (NASDAQ:LFWD) Stock
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts. ...
2026-07-07 16:15:00
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones
2026-06-25 12:00:00
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
2026-05-19 08:00:00
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
2026-05-15 11:20:46
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
2026-05-15 11:05:19
Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.
Lifeward Reports First Quarter 2026 Financial Results
2026-05-15 08:00:00
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in o perating expenses and cash utilization as company prepares to scale neurorehabilit ati on products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass.
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
2026-05-11 09:25:00
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026.
2026-05-04 08:00:00
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles and bone health conditions Findings reinforce safety profile and support expanded adoption of ReWalk for spinal c ord injury mobility Lifeward CEO Mark Gr ant addressed the 53 rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Frequently Asked Questions
-
What is the current Lifeward Ltd. (LFWD) stock price?
-
Lifeward Ltd.(NASDAQ:LFWD) stock price is $7.91 in the last trading session. During the trading session, LFWD stock reached the peak price of $10.56 while $4.14 was the lowest point it dropped to. The percentage change in LFWD stock occurred in the recent session was 0.89% while the dollar amount for the price change in LFWD stock was $0.07.
-
LFWD's industry and sector of operation?
-
The NASDAQ listed LFWD is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of LFWD?
-
Jeannine Lynch | Vice President of Market Access & Strategy
William Mark Grant | President, Chief Executive Officer & Director
Keith Dale Rose | Chief Medical Officer
Judy Kula | Vice President of Customer Service, Human Resources & Business Affairs
Miri Pariente | Vice President of Operations, Regulatory & Quality -
How many employees does LFWD have?
-
Number of LFWD employees currently stands at 81. LFWD operates from 3 Hatnufa Street, Yokneam Illit, MA 2069203, IL.
-
Link for LFWD official website?
-
Official Website of LFWD is: https://golifeward.com
-
How do I contact LFWD?
-
LFWD could be contacted at phone #972 4 959 0123 and can also be accessed through its website. LFWD operates from 3 Hatnufa Street, Yokneam Illit, MA 2069203, IL.
-
How many shares of LFWD are traded daily?
-
The average number of LFWD shares traded daily for last 3 months was 12.23K.
-
What is the market cap of LFWD currently?
-
The market value of LFWD currently stands at $12.74M with its latest stock price at $7.91